FAQ/Help |
Calendar |
Search |
Today's Posts |
![]() |
#1 | ||
|
|||
Senior Member
|
Alpha-synuclein is thought to play a role in the pathogenesis of PD. The problem is not simply a case of having too much alpha-synuclein, but rather a case of the misfolding of the protein leading to its aggregation.
Clearly, being able to control the aggregation would have theraputic implications. In a paper published 5 years ago, Osawa et al. reported: "The aggregation of alpha-synuclein without comformational change occurred rapidly when a voltage of 1V was applied." Unfortunately, this is the opposite effect to that required. Does anyone know of any later work in this area? Tag johnt:alpha-synuclein Reference [1] "Aggregation and Fibrillation Study of alpha-synuclein Under Applied Voltage" Osawa, et al. Electrochemistry, 2008 https://www.jstage.jst.go.jp/article.../76_8_614/_pdf
__________________
Born 1955. Diagnosed PD 2005. Meds 2010-Nov 2016: Stalevo(75 mg) x 4, ropinirole xl 16 mg, rasagiline 1 mg Current meds: Stalevo(75 mg) x 5, ropinirole xl 8 mg, rasagiline 1 mg |
||
![]() |
![]() |
|
|
![]() |
||||
Thread | Forum | |||
drug stops iron interaction with dopamine and interrupts alpha synuclein aggregation | Parkinson's Disease | |||
Too much or too little alpha-synuclein | Parkinson's Disease | |||
Alpha-synuclein | Parkinson's Disease | |||
Alpha synuclein | Parkinson's Disease |